9 completed, 1 terminated, 1 unknown. 11 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 11 | Completed 9, Terminated 1, Unknown 1 |
Follow Cellulite: new trials by email Literature Review of Cellulite trials Research Report on Cellulite
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Efficacy and Safety of CBL-514 in Participants With EFP; Cellulite (Stage 2) CBL-514 injection - Cellulite | Phase 2 | Completed | Caliway Biopharmaceuticals Co., Ltd. | 23 | 2023-05-10 | 2026-07-09 |
| A Study to Evaluate the Efficacy and Safety of CBL-514 in Participants With EFP; Cellulite (Stage 1) 40 mg CBL-514, 60 mg CBL-514, 80 mg CBL-514 - Cellulite | Phase 2 | Completed | Caliway Biopharmaceuticals Co., Ltd. | 12 | 2023-01-09 | 2026-10-21 |
| Study of Different Interventions to Reduce Bruising Following CCH-Aaes Treatment for Cellulite of the Buttocks CCH-aaes, Antifibrinolytic Agent - Edematous Fibrosclerotic Panniculopathy, Cellulite | Phase 2 | Completed | Endo USA Inc., a Keenova Therapeutics Company | 91 | 2022-06-15 | 2025-03-07 |
| CCH Treatment of Cellulite in the Presence of Dermal Laxity With Comparison Between Two (2) Different Injection Techniques collagenase clostridium histolyticum - Edematous Fibrosclerotic Panniculopathy, Cellulite | Phase 2 | Completed | Endo USA Inc., a Keenova Therapeutics Company | 35 | 2020-10-01 | 2022-09-28 |
| Impact of CCH Treatment of Buttock and Thigh Cellulite in Adult Women EN3835 - Cellulite, Edematous Fibrosclerotic Panniculopathy (EFP) | Phase 2 | Terminated | Endo USA Inc., a Keenova Therapeutics Company | 7 | 2019-11-20 | 2021-10-07 |
| Injection Techniques of Collagenase Clostridium Histolyticum (CCH) for the Treatment of EFP (Cellulite) collagenase clostridium histolyticum (CCH) - Edematous Skin | Phase 2 | Completed | Endo USA Inc., a Keenova Therapeutics Company | 64 | 2018-09-18 | 2023-09-07 |
| Safety and Effectiveness of EN3835 in the Treatment of EFP in Women Collagenase Clostridium Histolyticum - Edematous Fibrosclerotic Panniculopathy, Cellulite | Phase 2 | Completed | Endo USA Inc., a Keenova Therapeutics Company | 158 | 2017-11-17 | 2020-12-29 |
| EN3835 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite) Collagenase Clostridium Histolyticum - Edematous Fibrosclerotic Panniculopathy, Cellulite | Phase 2 | Completed | Endo USA Inc., a Keenova Therapeutics Company | 259 | 2016-10-05 | 2020-11-24 |
| EN3835 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite) COLLAGENASE CLOSTRIDIUM HISTOLYTICUM, Placebo Comparator - Edematous Fibrosclerotic Panniculopathy, Cellulite | Phase 2 | Completed | Endo USA Inc., a Keenova Therapeutics Company | 375 | 2016-02-01 | 2017-11-06 |
| A Phase 2, Randomized, Double-blind, Placebo Controlled Dose Ranging Study of Repeat Doses of AA4500 for the Treatment of Edematous Fibrosclerotic Panniculopathy Collagenase Clostridium Histolyticum, Placebo - Edematous Fibrosclerotic Panniculopathy (EFP) | Phase 2 | Completed | Endo USA Inc., a Keenova Therapeutics Company | 150 | 2013-10-01 | 2017-10-05 |
| Collagenase in the Treatment of Cellulite Collagenase, Biological - Cellulite | Phase 2 | Unknown | Stony Brook University | 20 | 2013-02-01 | 2012-12-12 |
Cutis Laxa (1)
Pathological Conditions, Signs and Symptoms (11) · Signs and Symptoms (11) · Skin Manifestations (11) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Connective Tissue Diseases (1) · Genetic Diseases, Inborn (1) · Skin Diseases (1) · Skin Diseases, Genetic (1) · Skin and Connective Tissue Diseases (1)
Microbial Collagenase (6) · Antifibrinolytic Agents (1) · Biological Products (1) · Collagenases (1) · xiapex (1)
Endo USA Inc., a Keenova Therapeutics Company (8) · Caliway Biopharmaceuticals Co., Ltd. (2) · Stony Brook University (1)
United States (11)
Anne Sheu (2) · David Hernandez (2) · Alexander B Dagum, MD (1) · Ashley Dayoub (1) · George Omburo (1) · Marie A Badalamente, PhD (1) · Mike McLane (1) · Mike McLane, PhD (1) · Veronica Urdaneta, MD MPH (1)